A more sensitive MS detector does not obviously lead to a more sensitive assay: Experiences with ES-285

Biomedical Chromatography

Volumn 18, Issue 6, 2004, Pages 403-407

  Stokvis, Ellen ^a   Rosing, Hilde ^a   López Lázaro, Luis ^b   Schellens, Jan H M ^a,c   Beijen, Jos H ^a,c  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b PHARMAMAR S A   (Spain)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

API 3000; API 365; ES 285; LLOQ reduction

Indexed keywords

DRUG DOSAGE; DRUG PRODUCTS; LIQUID CHROMATOGRAPHY; PLASMA (HUMAN);

% REDUCTIONS; ANTI-CANCER AGENTS; API 3000; API 365; ES-285; HUMAN PLASMAS; LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY; LLOQ REDUCTION; QUANTITATIVE DETERMINATIONS; SENSITIVE ASSAY;

MASS SPECTROMETRY;

ANTINEOPLASTIC AGENT; ES 285; SPISULOSINE; UNCLASSIFIED DRUG;

ARTICLE; ASSAY; BLOOD SAMPLING; CALIBRATION; CONTROLLED STUDY; DEVICE; LIQUID CHROMATOGRAPHY; MASS SPECTROMETER; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY;

EID: 4344651474     PISSN: 02693879     EISSN: None     Source Type: Journal    
DOI: 10.1002/bmc.404     Document Type: Article

References (2)

1. FDA. Guidance for Industry: Bioanalytical Method Validation. US Food and Drug Administration, Center for Drug Evaluation and Research, 2001; www.fda.gov/cder/guidance/4252fnl.htm
2. Stokvis E, Nan-Offeringa L, Rosing H, López-Lázaro L, Aceña JL, Miranda E, Lyubimov A, Levine BS, D'Aleo C, Schellens JHM and Beijnen JH. Quantitative analysis of ES-285, an investigational marine anticancer drug, in human, mouse, rat, and dog plasma using coupled liquid chromatography and tandem mass spectrometry. Journal of Mass Spectrometry 1998; 38: 548.